Credit Suisse Bashes Arena Pharma (ARNA)
Interesting that CS chose to downgrade the obesity drug maker on the day of one of the biggest rallies in recent memory. The DOW rose +250 points, the Nasdaq +66 points, and the S&P 500 rose nearly +30 points today.
Shares of Arena were down -5%.
Kalowski, of Credit Suisse, initiated coverage of Orexigen with an Outperform rating and Arena with an Underperform. Kalowski already rates Vivus at Outperform.
Orexigen has a “favorable risk/reward profile around the pre-approval cardiovascular outcomes trial,” and Vivus as recent “concerns relate to matters that are not new.” But Arena’s prospects may not be as promising, says Kalowski.
“ARNA commendably ushered Belviq through FDA; we believe that sales (ARNA has an approximately 35% royalty) will fall short of the market’s lofty expectations,” he wrote.
Mastery Bottom Line
Mr. Kalowski of Credit Suisse must have written this little piece after snorting a fat line of bath salts.
Anyone who has been following Arena for a while knows that the stock has very low institutional ownership. In fact, around the time that Arena received its FDA approval for Belviq, it was approximately 20% institutional-owned. In the last couple of months it has risen to approximately 32%.
Credit Suisse doesn't have a crystal ball and neither do we. No one knows at this point whether doctors will prescribe Belviq more or Qnexa more. Arena has a lower risk profile so we tend to think that Belviq will be prescribed more, but again, we don't have a time machine.
This seems like a pretty blatant attempt from CS to hold the share-price down so intituitions can continue to back up the truck.
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Kurt Kallaus: Slow Growth Persists but US Recession Likely Still Years Away | Financial Sense
- Total Societal Collapse: What The Media Isn't Telling You About Venezuela | ZeroHedge
- Treasury Vol Crashes To 2016 Lows | ZeroHedge
- What Happens When Central Banks Become Major Buyers in the Stock Market? Case Study: Japan | Financial Sense
- Home Prices Are Soaring In America's 2nd Most Dangerous City | ZeroHedge
- 85% Of Wall Street Expects a "Dovish Hike Signal" From Yellen Tomorrow | ZeroHedge
- How to Leave the European Union | Financial Sense
The most relevant financial news and articles from the Internets
- Volkswagen reaches deal to compensate U.S. dealers:... | Business Insider
- Summer driving season is ending — here's how far $50 worth of... | Business Insider
- 'Pretty outrageous': Clinton campaign manager hits back at... | Business Insider
- A sleep doctor says Trump's 4 hour sleep schedule will... | Business Insider
- Salesforce CEO Marc Benioff relies on the same Zen Buddhist concept that... | Business Insider
- A professional matchmaker shares the 4 most important things she's... | Business Insider
- Putin: The ban on Russia's Paralympics team is inhumane | Business Insider